UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ACRV holding history
Acrivon Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ACRV overviewAll 13F holders of ACRVFull Q2 2026 holdings
- Shares (Q2 2026)
- 43,850
- Value
- $78.1K
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q4 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 43,850 | $78.1K | <0.1% | +9,216+26.6% | Added | Holders |
| Q1 2026 | 34,634 | $48.1K | <0.1% | −313,907−90.1% | Reduced | Holders |
| Q4 2025 | 348,541 | $840.0K | <0.1% | −334,677−49.0% | Reduced | Holders |
| Q3 2025 | 683,218 | $1.24M | <0.1% | +682,763+150,057.8% | Added | Holders |
| Q2 2025 | 455 | $541 | <0.1% | −12,433−96.5% | Reduced | Holders |
| Q1 2025 | 12,888 | $26.2K | <0.1% | −1,329−9.3% | Reduced | Holders |
| Q4 2024 | 14,217 | $85.6K | <0.1% | +8,555+151.1% | Added | Holders |
| Q3 2024 | 5,662 | $39.6K | <0.1% | −5,490−49.2% | Reduced | Holders |
| Q2 2024 | 11,152 | $64.7K | <0.1% | −1,593−12.5% | Reduced | Holders |
| Q1 2024 | 12,745 | $91.1K | <0.1% | +12,745 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −102−100.0% | Sold out | Holders |
| Q3 2023 | 102 | $975 | <0.1% | −9,678−99.0% | Reduced | Holders |
| Q2 2023 | 9,780 | $126.7K | <0.1% | +4,384+81.2% | Added | Holders |
| Q1 2023 | 5,396 | $68.5K | <0.1% | +648+13.6% | Added | Holders |
| Q4 2022 | 4,748 | $54.7K | <0.1% | +4,748 | New | Holders |